Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Consumer Enveric Biosciences Advances Mental Health Treatment with Neuroplasticity Enhancing Drug
enveric

Enveric Biosciences Advances Mental Health Treatment with Neuroplasticity Enhancing Drug

3rd January 2024

From its EVM301 portfolio, Enveric Biosciences has chosen EB-003 as its principal therapeutic prospect for managing mental health conditions. 

The treatment aids in enhancing neuroplasticity without inducing hallucinatory effects. 

Early-stage research on the medication is expected to start at the beginning of the upcoming year, and the company is looking into filing a request for their experimental drug for a phase I clinical study. The drug is aimed at treating anxiety and depression.  

Out of all the prospects, three drug treatments were selected, with EB-003 distinguishing itself for its extensive features. 

Joeseph Tucker, the leading executive of Enveric, commented, “Importantly, moving EB-003 into our development pipeline marks a transformative step for Enveric as we complete our period as a discovery phase company and fully transition to the next phase as a drug development company.” 

Tucker went on to add, “With EB-003, we have identified a novel, neuroplastogenic molecule that exhibits several key properties that align with favourable tolerability and efficacy in relevant animal models.” 

 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved. 

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.